<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934814</url>
  </required_header>
  <id_info>
    <org_study_id>TJ011133EDI101</org_study_id>
    <secondary_id>KEYNOTE KN-A21</secondary_id>
    <nct_id>NCT03934814</nct_id>
  </id_info>
  <brief_title>Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma</brief_title>
  <official_title>A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of TJ011133 in&#xD;
      participants with solid tumors and lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety,&#xD;
      tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD),&#xD;
      pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an&#xD;
      anti-CD47 antibody, in participants with advanced relapsed or refractory solid tumors and&#xD;
      lymphoma. The study will be conducted in 2 parts. Part 1 comprises a single agent dose&#xD;
      escalation (Part 1A) and 2 separate combination therapy dose escalations (Part 1B with&#xD;
      pembrolizumab and Part 1C with rituximab) and Part 2 includes a dose expansion study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">September 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>21 or 28 days, depending on study part</time_frame>
    <description>Part 1A DLT period is 3 weeks, Part 1B DLT period is 3 weeks, Part 1C DLT period is 4 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>The CTCAE criteria will be used to assess adverse events on this trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) for Both Monotherapy and Combination Therapy</measure>
    <time_frame>21 or 28 days, depending on study part</time_frame>
    <description>Based on DLT definitions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Tmax</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Time of peak concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Cmax</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Maximal concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: T1/2</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Investigational Product (IP) half-life (T1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: CL</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Investigational Product (IP) Clearance (CL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: AUC∞</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Area under the curve from time zero extrapolated to infinity (AUC∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADA)</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Incidence and concentration of anti-drug antibodies.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1A - TJ011133 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ011133 alone will be administered at up to 7 dose levels (0.3, 1, 3, 10, 20, 30, 45 mg/kg) once weekly (Q1W) (the 0.3 mg/kg dose level cohort will be enrolled if a DLT in 1 out of 3 subjects is observed following the 1 mg/kg dose level).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B - Combination therapy of TJ011133 with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ011133 will be administered Q1W, starting at 20 mg/ kg, in combination with pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1C - Combination therapy of TJ011133 with rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ011133 will be administered Q1W, starting at 20 mg/kg, in combination with rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 participants (with DLBCL or indolent lymphoma) in the TJ011133 combination therapy with rituximab expansion and 20 participants with solid tumors in the TJ011133 combination therapy with pembrolizumab expansion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ011133</intervention_name>
    <description>TJ011133 will be administered weekly.</description>
    <arm_group_label>Part 1A - TJ011133 Monotherapy</arm_group_label>
    <arm_group_label>Part 1B - Combination therapy of TJ011133 with pembrolizumab</arm_group_label>
    <arm_group_label>Part 1C - Combination therapy of TJ011133 with rituximab</arm_group_label>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered every 3 weeks.</description>
    <arm_group_label>Part 1B - Combination therapy of TJ011133 with pembrolizumab</arm_group_label>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab will be administered weekly for 5 doses, then followed by monthly doses.</description>
    <arm_group_label>Part 1C - Combination therapy of TJ011133 with rituximab</arm_group_label>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1: Participants with advanced relapsed/refractory solid tumors and lymphoma.&#xD;
&#xD;
          -  Part 2 with Rituximab: Participants with DLBCL or Indolent B-cell Lymphoma, with at&#xD;
             least one measurable lesion by Lugano and available fresh metastatic biopsy sample&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Part 2 with Pembrolizumab: Participants with locally advanced non-small-cell lung&#xD;
             carcinoma (NSCLC) with disease progression or immune-oncology treatment naive&#xD;
             Epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with at least&#xD;
             one measurable lesion defined by RECIST 1.1, and available fresh metastatic biopsy&#xD;
             prior to study entry.&#xD;
&#xD;
          -  All Parts: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 and&#xD;
             adequate bone marrow, renal, and liver functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with known symptomatic central nervous system tumors or known central&#xD;
             nervous system metastases or leptomeningeal disease requiring steroids. Participants&#xD;
             who document stable and central nervous system metastases and are off steroids for&#xD;
             more than 4 weeks may be enrolled in the study.&#xD;
&#xD;
          -  Participants with Burkitt's lymphoma, lymphoblastic lymphoma, Richter's&#xD;
             transformation, primary effusion lymphoma or chronic lymphocytic leukemia/small&#xD;
             lymphocytic lymphoma.&#xD;
&#xD;
          -  Participants with mantle cell lymphoma.&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac diseases.&#xD;
&#xD;
          -  Prior treatment with CD47 or SIRPα inhibitors.&#xD;
&#xD;
          -  Prior autologous stem cell transplant &lt;=3 months prior to starting study.&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant with either standard or reduced intensity&#xD;
             conditioning.&#xD;
&#xD;
          -  Prior chimeric antigen receptor or chimeric antigen receptor T-cell therapy.&#xD;
&#xD;
          -  History of autoimmune anemia or autoimmune thrombocytopenia.&#xD;
&#xD;
          -  Positive Direct Antiglobulin Test.&#xD;
&#xD;
          -  Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Xu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>I-Mab Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Site Head</last_name>
    <phone>301-294-4408</phone>
    <email>us.info@i-mabbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dayle Craig</last_name>
      <email>dc0350@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Lakshminarayanan Nandagopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>CANCERCENTERFEDREGREP@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mahesh Seetharam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yan Xing, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylie Boyhen, CCRP</last_name>
      <phone>203-752-7835</phone>
      <email>Kylie.boyhen@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Iris Isufi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>CANCERCENTERFEDREGREP@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Winston W Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Morris</last_name>
      <phone>765-446-5111</phone>
      <email>eamorris@horizonbioadvance.com</email>
    </contact>
    <investigator>
      <last_name>Wael A Harb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Answer Line</last_name>
      <phone>800-855-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Swiecicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute/Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirish M Gadgeel, MD</last_name>
      <phone>313-916-9365</phone>
    </contact>
    <investigator>
      <last_name>Shirish M Gadgeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Related Clinical Trials</last_name>
      <email>CANCERCENTERFEDREGREP@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Alex A Adjei, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin David, MD</last_name>
      <phone>732-235-2465</phone>
    </contact>
    <investigator>
      <last_name>Kevin David, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine M Diefenbach, MD</last_name>
      <phone>212-731-5670</phone>
      <email>Catherine.Diefenbach@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Catherine M Diefenbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Jordan Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harini Ramachandran</last_name>
      <email>harinir@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Ajay K Gopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

